Noting these apparently paradoxical effects on CCA, other clinical studies raised the issue of incretins (such as dipeptidyl peptidase 4 inhibitors (DDP4)) and GLP-1R agonists in increasing the risk of CCA [99]. The gene discussed is GLP1R; the disease is cholangiocarcinoma.